SEPTEMBER 2020
Intertrade Ireland Seedcorn Regional Finalists 2021
VascVersa reach regional finals in Intertrade Ireland Seedcorn Competition 2021. This Seedcorn investor readiness competition was a fantastic opportunity for the company to secure expert feedback...
MARCH 2021
Vascversa participated in 2021 Pulse event
VascVersa were awarded a place on a prestigious PULSE programme. This was a three-day leadership and entrepreneurship training programme developed by the BIA and the Francis Crick Institute.
APRIL 2021
NI’s First Cell Therapy Company Secure Six Figure Deal
Award winning Queen’s University spin out VascVersa has completed a six-figure deal in its first investment round led by QUBIS, with support from Co-Fund NI and a group of angel investors from...
NOVEMBER 2021
VascVersa attend Cell & Gene at the Abbey conference, Galway
VascVersa were excited to attend their first face to face event in 2021 at the beautiful Glenlo Abbey in Galway. This event hosted by HiTech Health was a three-day event featuring international experts...
DECEMBER 2021
VascVersa join the NA-ATCC
VascVersa were delighted to become an NA-ATCC partner. The consortium consists of twenty industry, NHS and academic organisations lead by...
FEBRUARY 2022
Successful Biomedical Catalyst Funding Award
VascVersa leads consortium to advance new cell therapy for the treatment of chronic non-healing wounds.
MARCH 2022
VascVersa Pitched at HBAN Ulster Investor Meeting
This face to face event supported by Clarendon Fund Managers provided a fantastic opportunity for the team to showcase ANGICYTE™ technology to a local investor network. VascVersa presented...
MARCH 2022
VascVersa proudly working with Anthony Nolan charity
VascVersa will work with Anthony Nolan Cell & Gene Therapy Services who will support the company by supplying high-quality cord material for VascVersa to facilitate their development of ANGICYTE™ technology.
AUGUST 2022
VascVersa completes second investment round
VascVersa completes second investment round to accelerate development of ground-breaking cell therapies.